Cogent Biosciences Reports US FDA’s NDA Acceptance of Bezuclastinib for NonAdvanced Systemic Mastocytosis (NonAdvSM)

Why It Matters

The acceptance moves the first disease‑modifying KIT inhibitor toward market, addressing a high‑unmet‑need rare disorder and expanding Cogent's multi‑indication platform.

Key Takeaways

• FDA accepted bezuclastinib NDA for NonAdvSM.
• SUMMIT trial met primary and secondary endpoints.
• 48‑week data show deepening clinical benefit.
• Positive bone mineral density and disease‑modification signals.
• Additional NDAs planned for GIST and AdvSM.

Pulse Analysis

Systemic mastocytosis is a rare clonal disorder driven by activating KIT mutations, leading to abnormal mast cell accumulation and organ dysfunction. Non‑advanced forms (NonAdvSM) affect quality of life but lack approved disease‑modifying therapies, creating a sizable unmet need. Cogent Biosciences’ bezuclastinib is a selective, oral KIT inhibitor designed to curb mast cell proliferation while sparing off‑target kinases. By targeting the root molecular driver, the drug promises a shift from symptom control toward true disease modification, a claim that has attracted investor and clinician attention alike.

The FDA’s acceptance of the new‑drug application rests on data from the pivotal SUMMIT trial, which achieved its primary efficacy endpoint and both secondary endpoints at 48 weeks. Patients experienced sustained reductions in serum tryptase and symptom scores, with a notable deepening of response over time. Bone mineral density, a secondary safety metric, improved, suggesting a broader physiologic benefit beyond mast cell suppression. Importantly, the trial demonstrated activity in sub‑populations with high‑risk disease, reinforcing the drug’s potential to address the most challenging NonAdvSM cases.

Regulatory timing positions bezuclastinib for a PDUFA decision by December 30 2026, giving Cogent a clear path to market entry if approved. The company is already leveraging the same molecule for two additional indications: a first‑line NDA for gastrointestinal stromal tumors resistant to imatinib slated for April 2026, and a separate submission for advanced systemic mastocytosis in the first half of 2026. Success across these indications could create a multi‑indication platform, elevate Cogent’s valuation, and significantly intensify competition with other KIT‑targeted agents in development worldwide.